文献速递临床试验与 GCP基础与转化研究

个性化新抗原癌症疫苗治疗卵巢癌的1期试验

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.
PubMed 文献 · Nat Med · 2026-10-14

本研究报道了一项1期临床试验,评估个性化新抗原靶向癌症疫苗(NeoVax)在高grade上皮性卵巢癌辅助治疗中的可行性与安全性。

要点

  • NeoVax联合延迟抗PD-1在铂敏感卵巢癌中未出现意外安全信号。
  • 无患者因毒性停止治疗。

核心结论

  • 个性化新抗原靶向疫苗NeoVax联合延迟抗PD-1在铂敏感卵巢癌患者中可行且未出现意外安全信号。

主要发现

  • 12例可评估Cohort B患者中9例接种(75%,90% CI 47-93%),9例Cohort A患者中1例接种(11%,90% CI 0.6-43%)。
  • 未出现意外安全信号,无患者因毒性停止治疗。
  • >70%所选靶标在诊断活检至疫苗接种中位6.5个月后仍可通过非侵入性cfDNA分析检测到。
  • 耐药肿瘤克隆反映影响抗原呈递的多种机制,提示疫苗施加的免疫选择压力。

临床怎么用

  • 该1期试验支持在铂敏感卵巢癌中进一步评估个性化新抗原疫苗联合延迟抗PD-1策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Personalized neoantigen-targeting cancer vaccines in the adjuvant setting are of increasing interest across malignancies. Here we report the results of a phase 1 clinical trial testing the feasibility and safety of personalized neoantigen-targeting cancer vaccines for high-grade epithelial ovarian cancer. 'NeoVax' consisted of pools of synthetic long peptides targeting patient-specific neoantigens admixed with the immunostimulant poly-ICLC, was combined with delayed administration of anti-PD-1 antibody, and was tested in ten patients (one newly diagnosed patient (Cohort A) and nine patients at first recurrence (Cohort B)) with platinum-sensitive ovarian cancer following standard-of-care platinum doublet chemotherapy. Nine of 12 evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%) and 1 of 9 Cohort A patients (11%, 90% CI 0.6-43%). No unexpected safety signals were encountered and no patients discontinued treatment due to toxicity. Across patients, >70% selected targets remained detectable by noninvasive cell-free DNA analysis despite a median of 6.5 months from the time of diagnostic biopsy to vaccine administration, during which, patients received standard-of-care chemotherapy. Biomarker analysis was suggestive of biologic activity of the vaccine in six of ten patients and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination. Resistant tumor clones reflected diverse mechanisms affecting antigen presentation, indicative of immune-selective pressure exerted by vaccination. Overall, the interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination. ClinicalTrials.gov identifier: NCT04024878 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Sellars MC, Frank JA, Shim B, et al. Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial. Nat Med. 2026. PMID: 42875558. doi:10.1038/s41591-026-04717-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。